Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Bristol-Myers Squibb board formed

  • News

Executive Summary

Following Oct. 4 finalization of merger. Squibb will be merged into Bristol-Myers through an exchange of 2.4 Bristol-Myers shares for each Squibb share. Newly elected members are President Richard Furlaud, Exec VP Wayne Davidson, RJR Nabisco CEO Louis Gerstner, Squibb Institute President Edgar Haber, MD, Exec VP Charles Heimbold, Squibb President Jan Leschly, former Mobil CEO Rawleigh Warner, and MIT Professor Alexander Rich, MD. The eight new directors join current members: Chairman and CEO Richard Gelb, Vice Chairman William Miller, former NL Industries Chairman Ray Adam, AT&T Chairman Robert Allen and former President William Ellinghaus, retired Cluett Peabody Chairman Henry Henley, American Express Chairman James Robinson and Champion International Chairman Andrew Sigler.

Table

View full table

Tags:
Latest Headlines

Australia Calls For Companion Testing Plans For Drugs Requiring A CDx

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

See All
UsernamePublicRestriction

Register

PS016342

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By